Details of the Drug Combination

General Information of Drug Combination (ID: DC967SO)

Drug Combination Name
Dactinomycin Nilotinib
Indication
Disease Entry Status REF
Invasive ductal carcinoma Investigative [1]
Component Drugs Dactinomycin   DM2YGNW Nilotinib   DM7HXWT
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: HS 578T
Zero Interaction Potency (ZIP) Score: 12.98
Bliss Independence Score: 13.26
Loewe Additivity Score: 10.38
LHighest Single Agent (HSA) Score: 10.21

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Dactinomycin
Disease Entry ICD 11 Status REF
Adult kidney Wilms tumor N.A. Approved [2]
Advanced cancer 2A00-2F9Z Approved [2]
Beckwith-Wiedemann syndrome N.A. Approved [2]
Childhood kidney Wilms tumor N.A. Approved [2]
Gestational trophoblastic neoplasia 2F33-2F76 Approved [2]
Hamartoma N.A. Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Wilms tumor N.A. Approved [2]
Dactinomycin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Breaker [8]
------------------------------------------------------------------------------------
Dactinomycin Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [9]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [11]
------------------------------------------------------------------------------------
Dactinomycin Interacts with 85 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Response To Substance [12]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Response To Substance [13]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Increases Expression [5]
Dihydropyrimidinase-related protein 4 (DPYSL4) OT3SBS2S DPYL4_HUMAN Increases Expression [5]
Integral membrane protein GPR137B (GPR137B) OT1CINQQ G137B_HUMAN Increases Expression [5]
Integrin alpha-IIb (ITGA2B) OT4Y17PY ITA2B_HUMAN Increases Expression [5]
Ras-related protein R-Ras (RRAS) OTBBF28C RRAS_HUMAN Increases Expression [5]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [5]
Stomatin (STOM) OTC8R6EH STOM_HUMAN Increases Expression [5]
Cellular retinoic acid-binding protein 2 (CRABP2) OTY01V9G RABP2_HUMAN Increases Expression [5]
Tyrosine-protein kinase receptor UFO (AXL) OTKA2SUX UFO_HUMAN Increases Expression [5]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Increases Expression [5]
Tumor necrosis factor ligand superfamily member 9 (TNFSF9) OTV9L89D TNFL9_HUMAN Increases Expression [5]
Galectin-7 (LGALS7) OTMSVI7R LEG7_HUMAN Increases Expression [5]
Large ribosomal subunit protein eL34 (RPL34) OT0U9VMQ RL34_HUMAN Increases Expression [5]
Rho GDP-dissociation inhibitor 2 (ARHGDIB) OT9PD6CS GDIR2_HUMAN Increases Expression [5]
Epithelial membrane protein 1 (EMP1) OTSZHUHQ EMP1_HUMAN Increases Expression [5]
Epithelial membrane protein 3 (EMP3) OTODMJ1D EMP3_HUMAN Increases Expression [5]
Protein ripply3 (RIPPLY3) OT1HK35I DSCR6_HUMAN Increases Expression [5]
Endonuclease III-like protein 1 (NTHL1) OTPQXPT1 NTH_HUMAN Decreases Expression [5]
Antigen peptide transporter 1 (TAP1) OTJL27PW TAP1_HUMAN Increases Expression [5]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [5]
Kinesin-like protein KIF1A (KIF1A) OT3JVEGV KIF1A_HUMAN Increases Expression [5]
Protein AF1q (MLLT11) OTG5RVHC AF1Q_HUMAN Increases Expression [5]
Laminin subunit gamma-2 (LAMC2) OTJMTM72 LAMC2_HUMAN Increases Expression [5]
Filamin-C (FLNC) OT3F8J6Y FLNC_HUMAN Increases Expression [5]
Immediate early response gene 5 protein (IER5) OTJPTXMD IER5_HUMAN Increases Expression [5]
Keratin, type II cytoskeletal 80 (KRT80) OTAU54U3 K2C80_HUMAN Increases Expression [5]
All-trans-retinol 13,14-reductase (RETSAT) OTC3AOPX RETST_HUMAN Increases Expression [5]
Interleukin-27 receptor subunit alpha (IL27RA) OTSQBAKI I27RA_HUMAN Increases Expression [5]
Neuropilin and tolloid-like protein 2 (NETO2) OT0YAMC0 NETO2_HUMAN Increases Expression [5]
Mitochondria-eating protein (SPATA18) OTOEHTHU MIEAP_HUMAN Increases Expression [5]
Phospholipase ABHD3 (ABHD3) OTH8P977 ABHD3_HUMAN Increases Expression [5]
Homer protein homolog 3 (HOMER3) OTQ6D9X1 HOME3_HUMAN Increases Expression [5]
BSD domain-containing protein 1 (BSDC1) OT853CP9 BSDC1_HUMAN Increases Expression [5]
Stathmin-3 (STMN3) OT20F289 STMN3_HUMAN Increases Expression [5]
Endothelial protein C receptor (PROCR) OTRHED17 EPCR_HUMAN Increases Expression [5]
Fatty acid desaturase 3 (FADS3) OT9RVXGE FADS3_HUMAN Increases Expression [5]
Protein O-mannosyl-transferase 1 (POMT1) OTGQSHL5 POMT1_HUMAN Increases Expression [5]
Tissue factor (F3) OT3MSU3B TF_HUMAN Decreases Expression [14]
Tumor protein p53-inducible protein 11 (TP53I11) OTFPDYZU P5I11_HUMAN Decreases Expression [15]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Decreases Expression [16]
CASP8 and FADD-like apoptosis regulator (CFLAR) OTX14BAS CFLAR_HUMAN Decreases Expression [17]
Mitogen-activated protein kinase kinase kinase 7 (MAP3K7) OTUXEASC M3K7_HUMAN Decreases Expression [18]
Prominin-1 (PROM1) OTBHV8NX PROM1_HUMAN Decreases Expression [19]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [18]
Low-density lipoprotein receptor (LDLR) OTH559LU LDLR_HUMAN Decreases Expression [20]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Response To Substance [21]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Decreases Expression [22]
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) OTBPMIMW G3P_HUMAN Increases Expression [18]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Activity [23]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Expression [24]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Secretion [22]
Proto-oncogene tyrosine-protein kinase ROS (ROS1) OTDSKUGE ROS1_HUMAN Increases Expression [18]
Fibroblast growth factor 2 (FGF2) OT7YUJ9F FGF2_HUMAN Decreases Expression [25]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Decreases Expression [26]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [27]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [28]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Decreases Expression [29]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Decreases Expression [30]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [19]
CCAAT/enhancer-binding protein beta (CEBPB) OTM9MQIA CEBPB_HUMAN Decreases Expression [18]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Decreases Expression [18]
Lamin-B1 (LMNB1) OT100T3P LMNB1_HUMAN Decreases Expression [18]
rRNA 2'-O-methyltransferase fibrillarin (FBL) OTRODIE5 FBRL_HUMAN Affects Localization [31]
DNA-directed RNA polymerase II subunit RPB1 (POLR2A) OTHJQ1DZ RPB1_HUMAN Decreases Phosphorylation [32]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [33]
Signal transducer and activator of transcription 1-alpha/beta (STAT1) OTLMBUZ6 STAT1_HUMAN Increases Expression [18]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Decreases Expression [18]
Caspase-2 (CASP2) OTUDYSPP CASP2_HUMAN Increases Cleavage [34]
Dual specificity mitogen-activated protein kinase kinase 4 (MAP2K4) OTZPZX11 MP2K4_HUMAN Decreases Expression [18]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Decreases Expression [18]
DNA repair protein RAD51 homolog 1 (RAD51) OTNVWGC1 RAD51_HUMAN Decreases Expression [35]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [36]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Expression [37]
Son of sevenless homolog 1 (SOS1) OTTCWXC3 SOS1_HUMAN Decreases Expression [18]
FAS-associated death domain protein (FADD) OTV7GFHH FADD_HUMAN Decreases Expression [18]
Growth arrest-specific protein 6 (GAS6) OTPOPUUE GAS6_HUMAN Increases Degradation [38]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Decreases Expression [18]
Bcl-2-binding component 3, isoforms 3/4 (BBC3) OTUAXDAY BBC3B_HUMAN Increases Expression [28]
Proheparin-binding EGF-like growth factor (HBEGF) OTLU00JS HBEGF_HUMAN Decreases Expression [25]
Transcription factor SOX-17 (SOX17) OT9H4WWE SOX17_HUMAN Decreases Localization [39]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Decreases Expression [19]
Hyaluronidase-1 (HYAL1) OT2SJN0X HYAL1_HUMAN Increases ADR [40]
Complement component 1 Q subcomponent-binding protein, mitochondrial (C1QBP) OTPYQX3K C1QBP_HUMAN Decreases Response To Substance [41]
------------------------------------------------------------------------------------
⏷ Show the Full List of 85 DOT(s)
Indication(s) of Nilotinib
Disease Entry ICD 11 Status REF
Chronic myelogenous leukaemia 2A20.0 Approved [4]
Nilotinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Fusion protein Bcr-Abl (Bcr-Abl) TTS7G69 BCR_HUMAN-ABL1_HUMAN Modulator [45]
------------------------------------------------------------------------------------
Nilotinib Interacts with 5 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [46]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [47]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [46]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [48]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [48]
------------------------------------------------------------------------------------
Nilotinib Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [49]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [50]
------------------------------------------------------------------------------------
Nilotinib Interacts with 35 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Affects Response To Substance [51]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Affects Response To Substance [52]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [53]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [53]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [53]
Acetyl-CoA carboxylase 1 (ACACA) OT5CQPZY ACACA_HUMAN Increases Phosphorylation [53]
Retinal dehydrogenase 2 (ALDH1A2) OTJB560Z AL1A2_HUMAN Decreases Expression [43]
Tyrosine-protein kinase ABL1 (ABL1) OT09YVXH ABL1_HUMAN Decreases Phosphorylation [44]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Increases Expression [44]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Secretion [54]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Expression [44]
Homeobox protein Hox-B7 (HOXB7) OTC7WYU8 HXB7_HUMAN Increases Expression [43]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [55]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [55]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Increases Expression [44]
Breakpoint cluster region protein (BCR) OTCN76C1 BCR_HUMAN Decreases Phosphorylation [56]
Transcription factor JunB (JUNB) OTG2JXV5 JUNB_HUMAN Increases Expression [44]
Homeobox protein Hox-B9 (HOXB9) OTMVHQOU HXB9_HUMAN Increases Expression [43]
Cyclic AMP-dependent transcription factor ATF-6 alpha (ATF6) OTAFHAVI ATF6A_HUMAN Decreases Expression [44]
Histidine decarboxylase (HDC) OT4WA5YQ DCHS_HUMAN Decreases Expression [57]
Paired box protein Pax-3 (PAX3) OTN5PJZV PAX3_HUMAN Decreases Expression [43]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Secretion [58]
Paired box protein Pax-6 (PAX6) OTOC9876 PAX6_HUMAN Increases Expression [43]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [44]
Crk-like protein (CRKL) OTOYSD1R CRKL_HUMAN Decreases Phosphorylation [44]
Glutamate--cysteine ligase regulatory subunit (GCLM) OT6CP234 GSH0_HUMAN Increases Expression [44]
Homeobox protein MOX-1 (MEOX1) OTJEMT2D MEOX1_HUMAN Decreases Expression [43]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Cleavage [55]
Mesoderm posterior protein 2 (MESP2) OT7H4LYA MESP2_HUMAN Decreases Expression [43]
Transcription factor 15 (TCF15) OTA6UCWC TCF15_HUMAN Decreases Expression [43]
Oligodendrocyte transcription factor 3 (OLIG3) OTU8XLAF OLIG3_HUMAN Increases Expression [43]
ER degradation-enhancing alpha-mannosidase-like protein 1 (EDEM1) OTWHN69S EDEM1_HUMAN Increases Expression [44]
Eyes absent homolog 1 (EYA1) OTHU807A EYA1_HUMAN Decreases Expression [43]
Forkhead box protein C2 (FOXC2) OT83P1E0 FOXC2_HUMAN Decreases Expression [43]
Neurogenin-2 (NEUROG2) OTAEMIGT NGN2_HUMAN Increases Expression [43]
------------------------------------------------------------------------------------
⏷ Show the Full List of 35 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Breast adenocarcinoma DCR9AWM MDA-MB-468 Investigative [1]
Carcinoma DCGVLUR RXF 393 Investigative [1]
Carcinoma DC7Q41C MCF7 Investigative [1]
Colon adenocarcinoma DC67T1X COLO 205 Investigative [1]
Colon carcinoma DCQRWQ2 KM12 Investigative [1]
Invasive ductal carcinoma DCFMU7K BT-549 Investigative [1]
Adenocarcinoma DC34ODN DU-145 Investigative [59]
Adenocarcinoma DCTG67T OVCAR3 Investigative [59]
Adenocarcinoma DCH2F7D NCIH23 Investigative [59]
Adenocarcinoma DCUMJIM A549 Investigative [59]
Adenocarcinoma DC20RVP HCC-2998 Investigative [59]
Adenocarcinoma DCV4IQJ HT29 Investigative [59]
Adenocarcinoma DC3PLKW SW-620 Investigative [59]
Adult acute myeloid leukemia DCEJQ6F HL-60(TB) Investigative [59]
Amelanotic melanoma DCJMEGJ MDA-MB-435 Investigative [59]
Amelanotic melanoma DCXP72L M14 Investigative [59]
Astrocytoma DCOZRY5 U251 Investigative [59]
Astrocytoma DCBR369 SNB-19 Investigative [59]
Chronic myelogenous leukemia DCHPRK5 K-562 Investigative [59]
Clear cell renal cell carcinoma DCX01HA A498 Investigative [59]
Cutaneous melanoma DCX85EY SK-MEL-5 Investigative [59]
Glioblastoma DCPYTQR SNB-75 Investigative [59]
Glioma DC0M6P8 SF-539 Investigative [59]
Glioma DCXSIKW SF-295 Investigative [59]
Glioma DCPI11Z SF-268 Investigative [59]
Large cell lung carcinoma DCADYYT NCI-H460 Investigative [59]
Lung adenocarcinoma DCFF2OX HOP-62 Investigative [59]
Lung adenocarcinoma DCM8FXY MDA-MB-231 Investigative [59]
Lung adenocarcinoma DCZ7MGM NCI-H522 Investigative [59]
Malignant melanoma DCK7KFG LOX IMVI Investigative [59]
Melanoma DCCPWCM MALME-3M Investigative [59]
Minimally invasive lung adenocarcinoma DCY1C4O NCI-H322M Investigative [59]
Mixed endometrioid and clear cell carcinoma DCKIUNT IGROV1 Investigative [59]
Plasma cell myeloma DCNTSG6 RPMI-8226 Investigative [59]
Pleural epithelioid mesothelioma DCTK8AR NCI-H226 Investigative [59]
Prostate carcinoma DCEANAZ PC-3 Investigative [59]
------------------------------------------------------------------------------------
⏷ Show the Full List of 36 DrugCom(s)

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 Dactinomycin FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050682.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5697).
5 Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
6 Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate. 2002 Dec 1;53(4):286-99. doi: 10.1002/pros.10155.
7 Endocrine disruptors fludioxonil and fenhexamid stimulate miR-21 expression in breast cancer cells. Toxicol Sci. 2013 Jan;131(1):71-83. doi: 10.1093/toxsci/kfs290. Epub 2012 Oct 10.
8 Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
9 Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 1995 Nov 15;55(22):5342-7.
10 Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005 Feb;46(2):224-35.
11 Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72.
12 Functional analysis of MRP1 cloned from bovine. FEBS Lett. 2002 Jun 19;521(1-3):211-3. doi: 10.1016/s0014-5793(02)02816-8.
13 Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1. Leuk Res. 2005 Apr;29(4):407-14. doi: 10.1016/j.leukres.2004.09.001.
14 Mechanisms of tissue factor induction by the uremic toxin indole-3 acetic acid through aryl hydrocarbon receptor/nuclear factor-kappa B signaling pathway in human endothelial cells. Arch Toxicol. 2019 Jan;93(1):121-136.
15 Possible roles of a tumor suppressor gene PIG11 in hepatocarcinogenesis and As2O3-induced apoptosis in liver cancer cells. J Gastroenterol. 2009;44(5):460-9. doi: 10.1007/s00535-009-0030-1. Epub 2009 Apr 1.
16 Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80. doi: 10.1093/jnci/djh322.
17 Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res. 2001 Feb;7(2):407-14.
18 Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. BMC Cancer. 2005 Jul 7;5:74. doi: 10.1186/1471-2407-5-74.
19 Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
20 Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression. J Biol Chem. 2020 Nov 20;295(47):15870-15882. doi: 10.1074/jbc.RA120.015623. Epub 2020 Sep 10.
21 Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-kappa B to protect endothelial cells from tumor necrosis factor-alpha-mediated apoptosis. J Biol Chem. 2002 May 17;277(20):17950-61. doi: 10.1074/jbc.M108317200. Epub 2002 Mar 5.
22 The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts. J Bone Joint Surg Am. 2001 Feb;83(2):201-11. doi: 10.2106/00004623-200102000-00007.
23 The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. Carcinogenesis. 2003 Oct;24(10):1601-14. doi: 10.1093/carcin/bgg116. Epub 2003 Jul 17.
24 T-2 toxin upregulates the expression of human cytochrome P450 1A1 (CYP1A1) by enhancing NRF1 and Sp1 interaction. Toxicol Lett. 2019 Oct 15;315:77-86. doi: 10.1016/j.toxlet.2019.08.021. Epub 2019 Aug 27.
25 Osmotic Induction of Angiogenic Growth Factor Expression in Human Retinal Pigment Epithelial Cells. PLoS One. 2016 Jan 22;11(1):e0147312. doi: 10.1371/journal.pone.0147312. eCollection 2016.
26 Ammonia promotes endothelial cell survival via the heme oxygenase-1-mediated release of carbon monoxide. Free Radic Biol Med. 2017 Jan;102:37-46. doi: 10.1016/j.freeradbiomed.2016.11.029. Epub 2016 Nov 17.
27 Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
28 Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes. Anticancer Drugs. 2007 Aug;18(7):763-72. doi: 10.1097/CAD.0b013e3280adc905.
29 Enhanced GRP78 protein expression via the IRE1/ASK1/p38 MAPK pathway during As(2)O(3)-induced endoplasmic reticulum stress in BEAS-2B cells. Toxicology. 2021 Oct;462:152962. doi: 10.1016/j.tox.2021.152962. Epub 2021 Sep 21.
30 Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide. PLoS One. 2014 Jun 23;9(6):e99993. doi: 10.1371/journal.pone.0099993. eCollection 2014.
31 Specific inhibition of rRNA transcription and dynamic relocation of fibrillarin induced by mercury. Exp Cell Res. 2000 Aug 25;259(1):225-38. doi: 10.1006/excr.2000.4923.
32 Phosphorylation of the RNA polymerase II largest subunit during heat shock and inhibition of transcription in HeLa cells. J Cell Physiol. 1994 Mar;158(3):417-26. doi: 10.1002/jcp.1041580305.
33 Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells. Int J Cancer. 2003 Dec 20;107(6):929-40. doi: 10.1002/ijc.11503.
34 Actinomycin D and staurosporine, potent apoptosis inducers in vitro, are potentially effective chemotherapeutic agents against glioblastoma multiforme. Cancer Chemother Pharmacol. 2000;45(2):149-56. doi: 10.1007/s002800050023.
35 Unpredicted Downregulation of RAD51 Suggests Genome Instability Induced by Tetrachlorobenzoquinone. Chem Res Toxicol. 2016 Dec 19;29(12):2184-2193. doi: 10.1021/acs.chemrestox.6b00369. Epub 2016 Nov 21.
36 Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene. 2005 Feb 10;24(7):1231-43. doi: 10.1038/sj.onc.1208290.
37 Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation. Br J Cancer. 2011 Jul 12;105(2):221-30. doi: 10.1038/bjc.2011.229.
38 Androgen receptor-dependent transactivation of growth arrest-specific gene 6 mediates inhibitory effects of testosterone on vascular calcification. J Biol Chem. 2010 Mar 5;285(10):7537-44. doi: 10.1074/jbc.M109.055087. Epub 2010 Jan 4.
39 A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
40 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
41 [Expression of C1QBP gene and its correlation with drug resistance in human resistance choriocarcinoma cell line]. Zhonghua Fu Chan Ke Za Zhi. 2014 Aug;49(8):616-20.
42 Assessment of the inhibition potential of Licochalcone A against human UDP-glucuronosyltransferases. Food Chem Toxicol. 2016 Apr;90:112-22.
43 Exposure-based assessment of chemical teratogenicity using morphogenetic aggregates of human embryonic stem cells. Reprod Toxicol. 2020 Jan;91:74-91. doi: 10.1016/j.reprotox.2019.10.004. Epub 2019 Nov 8.
44 Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide. Exp Biol Med (Maywood). 2013 Aug 1;238(8):932-42. doi: 10.1177/1535370213492689. Epub 2013 Jul 24.
45 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
46 Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
47 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
48 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
49 Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87.
50 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
51 Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells. Chem Biol Interact. 2014 Aug 5;219:203-10. doi: 10.1016/j.cbi.2014.06.009. Epub 2014 Jun 19.
52 Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels. Chem Biol Interact. 2017 Aug 1;273:171-179. doi: 10.1016/j.cbi.2017.06.012. Epub 2017 Jun 13.
53 Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
54 p53 Gene (NY-CO-13) Levels in Patients with Chronic Myeloid Leukemia: The Role of Imatinib and Nilotinib. Diseases. 2018 Jan 25;6(1):13. doi: 10.3390/diseases6010013.
55 Nilotinib reduced the viability of human ovarian cancer cells via mitochondria-dependent apoptosis, independent of JNK activation. Toxicol In Vitro. 2016 Mar;31:1-11. doi: 10.1016/j.tiv.2015.11.002. Epub 2015 Nov 6.
56 AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028.
57 The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. Blood. 2006 Nov 15;108(10):3538-47. doi: 10.1182/blood-2005-12-028456. Epub 2006 Jul 18.
58 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
59 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.